Banque Pictet & Cie SA Sells 51,728 Shares of Boston Scientific Co. (NYSE:BSX)

Banque Pictet & Cie SA decreased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 348,659 shares of the medical equipment provider's stock after selling 51,728 shares during the quarter. Banque Pictet & Cie SA's holdings in Boston Scientific were worth $31,142,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Compagnie Lombard Odier SCmA raised its stake in shares of Boston Scientific by 74.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 5,402 shares of the medical equipment provider's stock valued at $483,000 after acquiring an additional 2,302 shares during the last quarter. Catalyst Financial Partners LLC raised its position in Boston Scientific by 2.2% in the 4th quarter. Catalyst Financial Partners LLC now owns 7,127 shares of the medical equipment provider's stock valued at $637,000 after purchasing an additional 154 shares during the last quarter. Asset Management One Co. Ltd. boosted its stake in Boston Scientific by 8.3% in the fourth quarter. Asset Management One Co. Ltd. now owns 696,124 shares of the medical equipment provider's stock worth $63,090,000 after purchasing an additional 53,471 shares in the last quarter. G&S Capital LLC grew its holdings in shares of Boston Scientific by 99.3% during the fourth quarter. G&S Capital LLC now owns 27,242 shares of the medical equipment provider's stock worth $2,433,000 after purchasing an additional 13,572 shares during the last quarter. Finally, Avestar Capital LLC raised its holdings in shares of Boston Scientific by 40.2% in the fourth quarter. Avestar Capital LLC now owns 17,381 shares of the medical equipment provider's stock valued at $1,552,000 after buying an additional 4,984 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity

In other news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares of the company's stock, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,527 shares of company stock valued at $8,801,626 over the last three months. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 0.7 %

Shares of Boston Scientific stock traded down $0.79 on Tuesday, reaching $105.32. 6,505,334 shares of the company were exchanged, compared to its average volume of 6,108,297. The company has a market capitalization of $155.22 billion, a price-to-earnings ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17. The company has a 50-day moving average of $96.79 and a 200 day moving average of $88.61.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. On average, equities research analysts forecast that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. Truist Financial raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. UBS Group upped their price objective on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Bank of America lifted their target price on Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Canaccord Genuity Group raised their price target on Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. Finally, Mizuho boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. One equities research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $107.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.